As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Ascletis's news arrives shortly after Eli Lilly reported favourable Phase III weight loss data for its oral GLP-1RA, ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Wellness influencer Janelle Rohner reveals she is 'microdosing' GLP-1 medication for weight loss and addresses criticism over ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about ...

researchers at Rutgers University in the USA investigated the relationship between individuals' body image and their interest in using glucagon-like peptide-1 agonists (GLP-1s) for weight loss.

Ascletis has announced its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved early weight loss in a Phase Ib trial and is now preparing to progress to a Phase IIa study.

Use of GLP-1 receptor agonists was associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor ...